Scientists map genetic clues after key lung cancer drug fails
NCT ID NCT05219162
Summary
This study aimed to understand why a common first-line lung cancer drug (osimertinib) stops working for some patients. Researchers analyzed genetic material from 182 patients with advanced lung cancer after their disease progressed on this drug. By comparing tissue and blood samples, they sought to identify specific genetic changes that could help doctors choose the next best treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100210, China
-
Research Site
Changsha, 410013, China
-
Research Site
Chengdu, 610014, China
-
Research Site
Dalian, 116023, China
-
Research Site
Foshan, 528000, China
-
Research Site
Fuzhou, 350014, China
-
Research Site
Harbin, 150081, China
-
Research Site
Hefei, 230001, China
-
Research Site
Hefei, 230601, China
-
Research Site
Linhai, 317000, China
-
Research Site
Luoyang, 471003, China
-
Research Site
Rizhao, 276826, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Taizhou, 225300, China
-
Research Site
Tianjin, 300060, China
-
Research Site
Zhengzhou, 450000, China
Conditions
Explore the condition pages connected to this study.